There are currently 24 clinical trials in Lake City, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Multi-Specialty Research Associates, Inc and Wr-Msra, Llc. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
MK-0616 (Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
Recruiting
This is a phase 3, randomized, placebo-controlled study of the efficacy and safety of MK-0616, an oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in participants with high cardiovascular risk. The primary objective is to evaluate the efficacy of MK-0616 compared with placebo in increasing the time to the first occurrence of major adverse cardiovascular events (MACE) including coronary heart disease (CHD) death, ischemic stroke, myocardial infarction (MI), acute limb ischemi... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2024
Locations: East Coast Institute for Research ( Site 0034), Lake City, Florida
Conditions: Arteriosclerosis, Hypercholesterolaemia
Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications
Recruiting
This study is being conducted to evaluate the efficacy and tolerability of rimegepant for migraine prophylaxis in adults with a history of inadequate response to oral preventive medications
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2024
Locations: Wr-Msra,Llc, Lake City, Florida
Conditions: Migraine
To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation
Recruiting
ABN401-003 is a Phase 2 clinical study to assess efficacy, safety, tolerability and pharmacokinetic profile of ABN401 in specific populations of advance solid tumors with c-MET alterations as monotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2024
Locations: Cancer Care of North Florida, PA (Lake City Cancer Care, LLC) - Medical Oncology, Lake City, Florida
Conditions: Advanced Solid Tumors
A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years
Recruiting
The purpose of this study is to demonstrate the efficacy of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) compared to placebo in the prevention of the first invasive extraintestinal pathogenic Escherichia coli disease (IED) event caused by ExPEC9V O-serotypes.
Gender:
All
Ages:
60 years and above
Trial Updated:
06/18/2024
Locations: Multi-Specialty Research Associates, Inc., Lake City, Florida
Conditions: Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
Recruiting
The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in children and adolescents.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
06/17/2024
Locations: Multi-Specialty Research Associates, Inc., Lake City, Florida
Conditions: Pediatric Migraine
A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats
Recruiting
Hot flashes and night sweats (also known as vasomotor symptoms or VMS) are the most common symptoms which bother women in menopause. This study will follow women going through menopause who have hot flashes and night sweats that cause them bother. They will be starting a non-hormonal therapy prescribed by their healthcare provider (HCP) to treat these symptoms. The women will visit their HCP's office, research center, or both. They will receive prescriptions for the non-hormonal therapy from the... Read More
Gender:
Female
Ages:
Between 40 years and 75 years
Trial Updated:
06/11/2024
Locations: Multi-Specialty Research Associates, Inc., Lake City, Florida
Conditions: Hot Flashes
Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use
Recruiting
This study is being conducted to evaluate the efficacy and tolerability of rimegepant in a population of adults that are unsuitable for triptan medications due to a previous intolerance, lack of efficacy, or contraindication (including a history of clinically-relevant cardiovascular disease).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: Wr-Msra, Llc, Lake City, Florida
Conditions: Migraine
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
Recruiting
The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of moderate or severe migraine in children and adolescents (≥ 6 to < 18 years of age).
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
05/31/2024
Locations: Multi-Specialty Research Associates, Inc., Lake City, Florida
Conditions: Acute Treatment of Migraine
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
Recruiting
The primary purpose of this study is to assess the safety and tolerability of AB598 when taken alone, and in combination with zimberelimab and standard chemotherapy in participants with advanced malignancies.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/23/2024
Locations: Lake City Cancer Care, LLC., Lake City, Florida
Conditions: Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer (GEJ), Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Renal Cell Carcinoma (RCC), Triple Negative Breast Cancer (TNBC)
A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Erosive Esophagitis
Recruiting
The objective of the Healing Phase of the study is to evaluate the safety and efficacy of up to 8 weeks of once daily oral administration of BLI5100 versus a PPI control in healing EE. The objective of the Maintenance Phase of the study is to evaluate the safety and efficacy of 24 weeks of once daily oral administration of BLI5100 (low or high dose) versus a PPI control in the maintenance of healed EE.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
05/14/2024
Locations: Research Site 09, Lake City, Florida
Conditions: Erosive Esophagitis
Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-2)
Recruiting
Primary Objective: Primary population (former smokers cohort): Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate-or-severe COPD exacerbations in former smokers with moderate-to-severe COPD Secondary Objectives: Primary population (former smokers cohort): Evaluate the efficacy of itepekimab compared with placebo on pulmonary function in former smokers with moderate-to-severe COPD Evaluate the efficacy of itepekimab compared with placebo on occ... Read More
Gender:
All
Ages:
Between 40 years and 85 years
Trial Updated:
05/08/2024
Locations: Multi-Specialty Research Associates, Inc Site Number : 8400044, Lake City, Florida
Conditions: Chronic Obstructive Pulmonary Disease
Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD
Recruiting
This study will be conducted as a multi-center, randomized, double-blind, placebo-controlled trial to evaluate the effect of MHS-1031 on heartburn-free days in subjects with GERD-related heartburn symptoms.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/08/2024
Locations: Wr-Msra, Llc, Lake City, Florida
Conditions: Gastroesophageal Reflux